Contrive Datum Insights has published "Monogenetic Disorders Testing Market Size, Share & Industry Analysis, By Test type (Diagnostic Testing, Prenatal Testing, Carrier Testing, New-Born Screening, Predictive and Pre-Symptomatic Testing), Disease type (Thalassaemia, Sickle Cell Anemia, Cystic fibrosis, Familial Hypercholesterolemia, Huntington's Disease, Severe Combined Immunodeficiency (SCID), Polycystic Kidney Disorder, Neurofibromatosis, Gaucher's Disease, Tay-Sachs Disorder), End-user (Hospitals, Specialized Clinics, Ambulatory Surgical Centers), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Sanger Sequencing, Microarray, Fluorescence In Situ Hybridization (FISH)), Product & service (Reagents & Consumables, Instruments, Software & Services), and Regional Forecast, 2026-2034". The study sizes the global monogenetic disorders testing market at USD 650 million in 2025 and projects growth from USD 715 million in 2026 to USD 1692.1 million by 2034, a compound annual growth rate of 11.37% across the forecast period.
Monogenetic disorders testing covers laboratory assays that detect single-gene mutations responsible for inherited conditions such as cystic fibrosis, sickle cell anemia and Tay-Sachs disorder, delivered through carrier screening, diagnostic confirmation, newborn panels, predictive testing and prenatal analysis. Testing is performed on blood, saliva or amniotic samples using PCR, next-generation sequencing, Sanger sequencing, microarray or FISH platforms. Buyers include hospital laboratories, specialized genetic clinics and ambulatory centers that order these assays on behalf of clinicians, expectant parents and at-risk families.
Rising global prevalence of inherited disorders and expanding newborn screening mandates
Rising global prevalence of inherited disorders and expanding newborn screening mandates is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.37% a year, the test type lines exposed to it move fastest: Prenatal Testing compounds at 13.93%, taking its share of revenue from 24% to 29.58% and its value from USD 156 million to USD 500.5 million.
On the upside, the study's bull case assumes sequencing cost declines faster than the base case and newborn screening mandates expand into additional jurisdictions sooner, pulling adoption of next-generation sequencing based panels forward across all five test types, which would take 2034 revenue to USD 1874.9 million rather than the USD 1692.1 million base case.
However, reimbursement expansion for genetic testing stalls in emerging markets and the shortage of trained genetic counselors persists longer than assumed, slowing the conversion of eligible patients into tested patients across carrier, predictive and prenatal testing, which would hold 2034 revenue to USD 1539.8 million. Diagnostic Testing, which carries 31.98% of 2025 revenue, already grows at only 10.32% against the market's 11.37%, so the largest part of the base is also its slowest.
Key Players Compete on Diagnostic Testing Volume and Prenatal Testing Growth
Competition in the global monogenetic disorders testing market runs along the test type axis rather than the regional one. Diagnostic Testing holds 31.98% of 2025 revenue at USD 207.9 million and remains the largest line through 2034 at 29.26%, making it the position hardest for a challenger to take. Prenatal Testing, growing at 13.93%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 650 million.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Test type | Diagnostic Testing | 31.98% · USD 207.9 million | — |
| Disease type | Thalassaemia | 18% · USD 117 million | Familial Hypercholesterolemia 14.01% |
| End-user | Hospitals | 52% · USD 338 million | Specialized Clinics 12.6% |
| Technology | Next-Generation Sequencing (NGS) | 34% · USD 221 million | — |
| Product & service | Reagents & Consumables | 58% · USD 377 million | Software & Services 14.83% |
- Based on regional analysis, North America led the global monogenetic disorders testing market in 2025 with 41.86% of global revenue at USD 272.1 million, reaching USD 643 million by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22.5% in 2025 to 27% in 2034, with revenue growing from USD 146.3 million to USD 456.9 million.
- Middle East and Africa remains the smallest region throughout, at 3.86% of 2025 revenue and 4.5% by 2034.
- Prenatal Testing is projected to grow at 13.93% over the forecast period, the fastest of any test type line.
- The United States is the largest single country market at USD 239.4 million in 2025, 36.83% of global revenue.
The report segments the market across five axes; by test type, and by disease type, end-user, technology and product & service; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 1539.8 million and USD 1874.9 million by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.